ICML 2023 | Insights into the activity of NX-2127 in patients with R/R B-cell malignancies
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, gives an overview of the mechanism of action of BTK degraders, and highlights the value of these agents as an option for patients who develop resistance to both covalent and non-covalent BTK inhibitors. Prof. Danilov then discusses a Phase I study evaluating the safety and activity of NX-2127, a novel BTK degrader, in patients with relapsed/refractory (R/R) B-cell malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). This agent has shown promising preliminary efficacy in this patient population, with a fairly manageable toxicity profile. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
A.V.D. has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Lilly Oncology, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix, TG Therapeutics and Takeda Oncology.
